CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS
CASI Pharmaceuticals reported a 26% increase in third-quarter revenue, reaching $10.2 million from $8.1 million year-over-year, attributed mainly to EVOMELA sales. During this period, research and development expenses rose to $3.9 million, reflecting ongoing clinical projects like BI-1206 and CID-103. Notably, costs of revenues increased to $4.2 million, while general and administrative expenses decreased to $4.8 million. Despite strong performance in sales, the ongoing COVID-related restrictions in China may impact future revenue.
- Revenue for Q3 2022 at $10.2 million, up 26% from Q3 2021.
- First patient dosed in BI-1206 Phase I trial in China.
- CNCT-19 NDA submission is on track.
- COVID restrictions in China may adversely affect future sales activities.
ROCKVILLE, Md. and BEIJIN, Nov. 14, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the third quarter of 2022.
Wei-Wu He, Ph.D., CASI's Chairman and Chief Executive Officer, commented, "We are pleased to report
Dr. He continued, "Advancement, development, and commercialization of the portfolio remains our strategic focus. Through our partner Juventas, the CNCT-19 New Drug Application (NDA) submission to the National Medical Products Administration (NMPA) is on track, and we are in preparation for the anticipated CNCT-19 launch in China. As we continue the development of the regulatory framework for BI-1206 in China, we were pleased with the recent dosing of the first patient in the BI-1206 phase I trial in China. We expect CB-5339 to receive Clinical Trial Application approval from the NMPA in early 2023; Meanwhile, our CID-103's Phase I study continues. We plan to build on the momentum to drive our portfolio forward by executing on several milestones in the quarters ahead."
Third Quarter 2022 Financial Highlights
- Revenues consist primarily of product sales of EVOMELA. Revenue was
$10.2 million for the three months ended September 30, 2022, compared to$8.1 million for the three months ended September 30, 2021. - Costs of revenues consist primarily of the cost of inventories of EVOMELA and sales-based royalties related to the sale of EVOMELA. Costs of revenues were
$4.2 million for the three months ended September 30, 2022, compared to$3.4 million for the three months ended September 30, 2021. - Research and development expenses for the three months ended September 30, 2022, were
$3.9 million , compared with$2.9 million for the three months ended September 30, 2021. The increase of research and development expenses for the three months periods was mainly due to expense incurred for BI-1206 and CID-103. - General and administrative expenses for the three months ended September 30, 2022, were
$4.8 million , compared with$5.3 million for the three months ended September 30, 2021. - Selling and marketing expenses for the three months ended September 30, 2022, were
$3.6 million , compared with$3.4 million for the three months ended September 30, 2021. - Acquired in-process R&D expenses for the three months ended September 30, 2022 and 2021, were both nil.
- As of September 30, 2022, CASI had cash and cash equivalents of
$29.2 million .
Further information regarding the Company, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, can be found at www.casipharmaceuticals.com.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The majority of the Company's operations are now located in China. The Company is focused on acquiring, developing, and commercializing products that augment its hematology/oncology therapeutic focus as well as other areas of unmet medical need. The Company is executing its plan to become a biopharmaceutical leader by launching medicines in the greater China market, leveraging its China-based regulatory, clinical and commercial competencies and its global drug development expertise. The Company's operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd., located in Beijing, China. The Company has built a commercial team of more than 100 hematology and oncology sales and marketing specialists based in China. More information on CASI is available at www.casipharmaceuticals.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations, and goals. Forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on The Nasdaq Capital Market; the volatility in the market price of our common stock; the outbreak of the COVID-19 pandemic and its effects on global markets and supply chains; the risk of substantial dilution of existing stockholders in future stock issuances; the difficulty of executing our business strategy in China; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates or future candidates, including with respect to BI-1206, CB-5339 and CID-103; our lack of experience in manufacturing products and uncertainty about our resources and capabilities to do so on a clinical or commercial scale; risks relating to the commercialization, if any, of our products and proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks); our inability to predict when or if our product candidates will be approved for marketing by the U.S. Food and Drug Administration (FDA), National Medical Products Administration (NMPA), or other regulatory authorities; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates or future candidates, including with respect to our partnerships with Juventas and BioInvent; the risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; the risks associated with our product candidates, and the risks associated with our other early-stage products under development; the risk that result in preclinical and clinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; our ability to protect our intellectual property rights; our ability to design and implement a development plan for our ANDAs held by CASI Wuxi; the lack of success in the clinical development of any of our products; and our dependence on third parties; the risks related to our dependence on Juventas to conduct the clinical development of CNCT19 and to partner with us to co-market CNCT19; risks related to our dependence on Juventas to ensure the patent protection and prosecution for CNCT19; risks relating to the commercialization, if any, of our proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks); risks relating to interests of our largest stockholders and our Chairman and CEO that differ from our other stockholders; and risks related to the development of a new manufacturing facility by CASI Wuxi. Such factors, among others, could have a material adverse effect upon our business, results of operations, and financial condition. We caution readers not to place undue reliance on any forward-looking statements, which only speak as of the date made. Additional information about the factors and risks that could affect our business, financial condition, and results of operations, are contained in our filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.
EVOMELA® is proprietary to Acrotech Biopharma Inc. and its affiliates.
COMPANY CONTACT:
Rui Zhang
CASI Pharmaceuticals, Inc.
Phone: 240.864.2643
Email: ir@casipharmaceuticals.com
(Financial Table Follows)
CASI Pharmaceuticals, Inc. | |||||||
September 30, 2022 | December 31, 2021 | ||||||
ASSETS | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 26,742 | $ | 38,704 | |||
Restricted cash | 2,500 | — | |||||
Investment in equity securities, at fair value | 6,309 | 9,868 | |||||
Accounts receivable, net of | 12,560 | 9,803 | |||||
Inventories | 5,773 | 1,907 | |||||
Prepaid expenses and other | 1,728 | 1,688 | |||||
Total current assets | 55,612 | 61,970 | |||||
Property, plant and equipment, net | 13,867 | 12,712 | |||||
Intangible assets, net | 10,049 | 12,203 | |||||
Long-term investments | 39,780 | 40,128 | |||||
Right of use assets | 7,666 | 9,107 | |||||
Other assets | 932 | 2,178 | |||||
Total assets | $ | 127,906 | $ | 138,298 | |||
LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST AND | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 3,098 | $ | 4,789 | |||
Bank borrowings | 3,000 | — | |||||
Accrued and other current liabilities | 23,651 | 8,397 | |||||
Total current liabilities | 29,749 | 13,186 | |||||
Deferred income | 2,488 | 2,828 | |||||
Other liabilities | 12,455 | 14,325 | |||||
Total liabilities | 44,692 | 30,339 | |||||
Commitments and contingencies | |||||||
Redeemable noncontrolling interest, at redemption value | 21,503 | 23,457 | |||||
Stockholders' equity: | |||||||
Preferred stock, | — | — | |||||
Outstanding | |||||||
Common stock, | |||||||
250,000,000 shares authorized at September 30, 2022 and December 31, 2021 | |||||||
13,733,459 shares and 13,987,578 shares issued at September 30, 2022 and | |||||||
13,606,130 shares and 13,979,624 shares outstanding at September 30, 2022 | 1,373 | 1,399 | |||||
Additional paid-in capital | 696,213 | 694,826 | |||||
Treasury stock, at cost: 127,329 shares and 7,954 shares held at | (9,068) | (8,034) | |||||
Accumulated other comprehensive income | (1,951) | 1,954 | |||||
Accumulated deficit | (624,856) | (605,643) | |||||
Total stockholders' equity | 61,711 | 84,502 | |||||
Total liabilities, redeemable noncontrolling interest and stockholders' equity | $ | 127,906 | $ | 138,298 | |||
CASI Pharmaceuticals, Inc. | |||||||||||||
Three Months Ended September 30 | Nine Months Ended September 30 | ||||||||||||
2022 | 2021 | 2022 | 2021 | ||||||||||
Revenues: | |||||||||||||
Product sales | $ | 10,213 | 8,075 | $ | 27,788 | $ | 20,900 | ||||||
Lease income from a related party | — | 37 | 60 | 110 | |||||||||
Total revenues | 10,213 | 8,112 | 27,848 | 21,010 | |||||||||
Costs of revenues | 4,247 | 3,417 | 11,555 | 8,757 | |||||||||
Gross Profit | 5,966 | 4,695 | 16,293 | 12,253 | |||||||||
Operating expenses: | |||||||||||||
Research and development | 3,905 | 2,895 | 11,748 | 10,408 | |||||||||
General and administrative | 4,849 | 5,259 | 15,694 | 16,249 | |||||||||
Selling and marketing | 3,566 | 3,433 | 10,241 | 9,508 | |||||||||
Acquired in-process research and development | — | — | — | 6,555 | |||||||||
Total operating expenses | 12,320 | 11,587 | 37,683 | 42,720 | |||||||||
Loss from operations | (6,354) | (6,892) | (21,390) | (30,467) | |||||||||
Non-operating income (expense): | |||||||||||||
Interest (expense)/income, net | (13) | 79 | 101 | 261 | |||||||||
Other income | 11 | 487 | 60 | 540 | |||||||||
Foreign exchange gains/(losses) | 637 | (6) | 2,325 | 289 | |||||||||
Change in fair value of investments | 696 | (3,687) | (2,012) | (205) | |||||||||
Impairment loss of long-term investments | — | — | — | (865) | |||||||||
Loss before income tax expense | (5,023) | (10,019) | (20,916) | (30,447) | |||||||||
Income tax expense | — | — | — | — | |||||||||
Net loss | (5,023) | (10,019) | (20,916) | (30,447) | |||||||||
Less: loss attributable to redeemable noncontrolling interest | (738) | (314) | (1,703) | (980) | |||||||||
Accretion to redeemable noncontrolling interest redemption value | 916 | 519 | 2,264 | 1,586 | |||||||||
Net loss attributable to CASI Pharmaceuticals, Inc. | $ | (5,201) | $ | (10,224) | $ | (21,477) | $ | (31,053) | |||||
Net loss per share (basic and diluted) | $ | (0.38) | $ | (0.73) | $ | (1.57) | $ | (2.30) | |||||
Weighted average number of common stock outstanding (basic | 13,606,130 | 13,979,636 | 13,668,553 | 13,486,024 | |||||||||
Comprehensive loss: | |||||||||||||
Net loss | $ | (5,023) | $ | (10,019) | $ | (20,916) | $ | (30,447) | |||||
Foreign currency translation adjustment | (3,127) | 15 | (6,420) | 848 | |||||||||
Total comprehensive loss | $ | (8,150) | $ | (10,004) | $ | (27,336) | $ | (29,599) | |||||
Less: Comprehensive loss attributable to redeemable noncontrolling interest | (2,074) | (309) | (4,218) | (712) | |||||||||
Comprehensive loss attributable to common stockholders | $ | (6,076) | $ | (9,695) | $ | (23,118) | $ | (28,887) | |||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/casi-pharmaceuticals-announces-third-quarter-2022-financial-results-301676268.html
SOURCE CASI Pharmaceuticals, Inc.
FAQ
What were the Q3 2022 earnings for CASI Pharmaceuticals?
What are the upcoming developments for CASI Pharmaceuticals?
How did COVID-19 impact CASI Pharmaceuticals' Q3 2022 performance?
